BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biocept, Inc. Publishes on Mechanics and Performance of Its OncoCEE(TM) Platform for Circulating Tumor Cells (CTCs) in Cancer Patients


9/29/2011 5:58:56 AM

SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced today the publication of a paper describing an analysis of CTC capture using its proprietary Cell Enrichment and Extraction (CEE) platform. The paper, appearing in the September issue of BioMicrofluidics and entitled "Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device," concludes that the CEE system conforms to simple physical principles and that it robustly and efficiently captures tumor cells under a variety of operating conditions. The Biocept technology platform may allow more sensitive and comprehensive CTC tests for cancer patients than currently available methodologies.

Biocept markets and sells OncoCEE-BR, a test for breast cancer utilizing CTCs, to community hospitals, pathologists and medical oncologists. The Company recently announced an agreement with Clarient, Inc., a GE Healthcare Company, to collaborate on the commercialization of this test, which will be performed in Biocept's laboratory. The test includes CTC enumeration and determination of the HER2 status of the detected CTCs by fluorescence in situ hybridization (FISH) from a simple blood sample. The Company plans to add ER/PR determination by Immunocytochemistry (ICC) and bone marrow analysis of disseminated tumor cells (DTCs) early in 2012 to the product offering. OncoCEE-BR is the first commercially available CTC test to include analysis of a specific treatment-associated biomarker.

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is a diagnostic and advanced laboratory services company specializing in the capture, detection, isolation and molecular analysis of circulating tumor cells (CTCs). Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes patented and innovative technologies to deliver clinically relevant information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with information highly relevant for the treatment of their patients with cancer.

SOURCE Biocept, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES